What Is the Scientific Evidence for Cartilage?
1 Wojtowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs R D (New Zealand) . 1999;1:117-129.
2 Dupont E, Savard PE, Jourdain C, et al. Antiangiogenic properties of a novel shark cartilage extract: Potential role in the treatment of psoriasis. J Cutan Med Surg . 1998;2:146-152.
3 Prudden JF, Nishihara G, Baker L. The acceleration of wound healing with cartilage-I. Surg Gynecol Obstet. 1957;105:283-287.
4 Dupont E, Savard PE, Jourdain C, et al. Antiangiogenic properties of a novel shark cartilage extract: Potential role in the treatment of psoriasis. J Cutan Med Surg . 1998;2:146-152.
5 Sheu JR, Fu CC, Tsai ML, et al. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res . 1998;18:4435-4441.
6 Davis PF, He Y, Furneaux RH, et al. Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc Res . 1997;54:178-182.
7 Oikawa T, Ashino-Fuse H, Shimamura M, et al. A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett. 1990;51:181-186.
8 McGuire TR, Kazakoff PW, Hoie EB, et al. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy. 1996;16:237-244.
9 Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science. 1983;221:1185-1187.
10 Riviere M, Latreille J, Falardeau P, et al. AE-941 (Neovastat), an inhibitor of angiogenesis: phase I/II cancer clinical trial results. Cancer Invest . 1999;17(suppl 1):16-17.
11 Jamali M-A, Riviere M, Falardeau P, et al. Effect of AE-941 (neovastat), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxicity prevention and survival. Clin Invest Med . 1998;(suppl):S16.
12 Riviere M, Falardeau P, Latreille J, et al. Phase I/II lung cancer clinical trial results with AE-941 (neovastat), an inhibitor of angiogenesis. Clin Invest Med . 1998;(suppl):S14.
13 Riviere M, Alaoui-Jamali M, Falardeau P, et al. Neovastat: an inhibitor of angiogenesis with anti-cancer activity. Presented at: American Association for Cancer Research Annual Meeting 39; March 28-April 1, 1998; New Orleans, LA.
14 Blasecki J, Alaoui-Jamali M, Wang T, et al. Oral administration of Neovastat inhibits tumor progression in animal models of progressive tumor growth and metastasis. Int J Oncol . 1997;11(suppl):934.
15 Dupont E, Alaoui-Jamali M, Wang T, et al. Angiostatic and antitumoral activity of AE-941 (Neovastat), a molecular fraction derived from shark cartilage. Presented at: American Association for Cancer Research Annual Meeting 38; April 12-16, 1997; San Diego, CA.
16 Horsman MR, Alsner J, Overgaard J. The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol. 1998;37:441-445.
17 Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998;16:3649-3655.
18 Ashar B, Vargo E. Shark cartilage-induced hepatitis. Ann Intern Med. 1996;125:780-781.
19 Loprinzi C, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer. Cancer . 2005 May 23.
20 Sussman, L. Shark cartilage shows no benefit as a therapeutic agent for lung cancer. EurekAlert! website. Available at: http://www.eurekalert.org/pub%5Freleases/2007-06/uotm-scs060107.php . Accessed June 19, 2007.
- Reviewer: EBSCO CAM Review Board
- Review Date: 09/2014 -
- Update Date: 09/18/2014 -